Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Silo Pharma (SILO) Equity Ratio (2019 - 2025)

Silo Pharma's Equity Ratio history spans 7 years, with the latest figure at 0.78 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 0.91% year-over-year to 0.78; the TTM value through Sep 2025 reached 0.78, down 0.91%, while the annual FY2024 figure was 0.68, 14.82% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.78 at Silo Pharma, up from 0.74 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.91 in Q3 2022 and bottomed at 0.68 in Q4 2024.
  • The 5-year median for Equity Ratio is 0.8 (2023), against an average of 0.8.
  • The largest annual shift saw Equity Ratio soared 218.56% in 2021 before it decreased 14.82% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.86 in 2021, then grew by 2.81% to 0.89 in 2022, then decreased by 10.22% to 0.8 in 2023, then fell by 14.82% to 0.68 in 2024, then increased by 15.5% to 0.78 in 2025.
  • Per Business Quant, the three most recent readings for SILO's Equity Ratio are 0.78 (Q3 2025), 0.74 (Q2 2025), and 0.68 (Q1 2025).